RxDoctor Payments Data

Roger Peck, MD

Internal Medicine · Manhattan, KSNPI 1972570331

Payments from drug & device makers

$304in general payments, 2019–2025

Across 21 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$73
  • Novo Nordisk$41
  • AstraZeneca$36
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27
  • Novartis$23
  • Amarin Pharma, Inc.$21
  • plus $83 from 6 others

What the payments were for

  • Food & beverage$304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$304 in reported general payments places this provider in the 60th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$195,512
Medicare patients
377
Services billed
3,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$70,244
FarxigaDapagliflozin Propanediol57$54,876
JardianceEmpagliflozin31$37,451
EliquisApixaban38$31,656
TrulicityDulaglutide23$25,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$22,949
JanuviaSitagliptin Phosphate24$22,937
XareltoRivaroxaban11$20,123
MounjaroTirzepatide11$19,873
Tresiba Flextouch U-100Insulin Degludec30$18,138
TradjentaLinagliptin14$9,296
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,238
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,918
Ventolin HfaAlbuterol Sulfate27$2,064
Pravastatin Sodium116$1,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$70,24450 claims
AstraZenecaFarxiga$36$54,87657 claims
Boehringer IngelheimJardiance, Tradjenta$12$46,74645 claims
PfizerEliquis$11$31,65638 claims
Johnson & JohnsonXarelto$15$20,12311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Manhattan

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →